Diagnostic solutions developer LynxDx has launched a new, non-invasive urine prostate cancer screening test, MyProstateScore 2.0 (MPS2).
A data-driven test, MPS2 has been designed to provide accurate and stratified risk assessment insights to guide clinical decisions for elevated prostate-specific antigen (PSA) patients or people with abnormal digital rectal exam (DRE) findings.
It offers an individualised risk score that helps physicians and patients make decisions on whether to proceed with a prostate biopsy.
The convenient, informative test allows doctors to improve prostate cancer screening accuracy compared to using PSA alone.
The foundation of MPS2 is a new gene fusion, T2:ERG, which is present in most prostate cancer patients. It is said to be the most specific prostate cancer biomarker.
MPS2 combines the specificity of the T2:ERG gene fusion with 17 other genetic biomarkers that help with clinically significant prostate cancer diagnoses.
It uses the 18 biomarkers to evaluate prostate cancer risk with a 99% negative predictive value (NPV) for patients with a prior negative biopsy and 95% NPV for biopsy-naïve patients.
LynxDx chief medical and commercial officer Spencer Heaton said: “MyProstateScore 2.0 is a highly accurate, non-invasive post-DRE urine test capable of assessing with precise accuracy a patient’s individualised risk of having clinically significant prostate cancer.
“This insight enables providers and patients to determine the most appropriate next steps in the patient’s care, as the path is unique for each person.
“By using MPS2, clinicians can more confidently inform their patients whether or not a clinically significant cancer is present, or if their elevated PSA result was due to other factors.”